|ID||Components||Size (96 tests)||Size (480 tests)|
|A004-214||Human CD47||35 μg||160 μg|
|A005-214||Biotinylated Human SIRP alpha||10 μg||10 μg|
|A003-214||Streptavidin-HRP||10 μg||10 μg|
|CD7-NA002||Anti-CD47 Neutralizing Antibody||20 μg||100 μg|
This pair is useful for screening for inhibitors of human CD47 binding to human SIRP alpha.
Upon receipt, please store all items at -70℃.
After reconstitution, the stock solution should be kept at -70℃.
It is recommended not to freeze thaw more than 3 times.
This product is stable after storage at:
Room temperature (RT) for 1 month in lyophilized state;
-20℃ for 1 year in lyophilized state;
-70℃ for 6 months under sterile conditions after reconstitution.
This inhibitor screening ELISA pair is designed to facilitate the identification and characterization of new CD47 pathway inhibitors. This assay employs a simple colorimetric ELISA platform, which measures the binding between immobilized human CD47 and in-house developed biotinylated SIRP alpha protein. This product is uniquely suitable for rapid high-throughput screening of putative CD47 inhibitors. Briefly, we provide you with a biotinylated human SIRP alpha protein, a human CD47 protein, an anti-CD47 neutralizing antibody (as method verified Reference), and Streptavidin-HRP reagent. Your experiment will include 4 simple steps:
a) Coat the plate with human CD47.
b) Mix biotinylated human SIRP alpha and your molecule of interest.
c) Add to the coated human CD47.
d) Add Streptavidin-HRP followed by TMB or other colorimetric HRP substrate.
Finally, the ability of your compound to inhibit CD47: SIRP alpha binding will be determined by comparing OD readings among different experimental groups.
Binding of Biotinylated Human SIRP alpha to Immobilized Human CD47 in a Functional ELISA Assay.
Immobilized human CD47 protein at 3 μg/mL (100 μL/well) can bind biotinylated human SIRP alpha with a linear range of 0.004-0.125 μg/mL when detected by Streptavidin-HRP. Background was subtracted from data points
Inhibition of CD47: SIRP alpha [Biotinylated] Binding by Anti-CD47 Neutralizing Antibody.
Serial dilutions of anti-CD47 neutralizing antibody (Catalog # CD7-NA002) (1:2 serial dilutions, from 10 μg/mL to 0.04 μg/mL) were added into CD47: biotinylated SIRP alpha binding reactions. The assay was performed according to the above described protocol. Background was subtracted from data points prior to log transformation and curve fitting.
Price(USD) : $600.00
Price(USD) : $2150.00
Emerging VoCs, Lambda, Delta, Beta, Alpha mutants and so on, including RBD, S trimer, S1, NTD, NP, etc. These mutants are of high purity and bioactivity and can be used to evaluate the efficacy of the antibodies and vaccination.
ELISA kits for neutralizing antibody titer assay, binding antibody titer assay, antibody isotype assay, antigen titer assay and inhibitor screening, etc., which can accelerate the research and development of anti-SARS-CoV-2 drugs and vaccines.
50+ targets designed for CAR detection, including PE/FITC/biotin labeled proteins. The key reagents for CD19 and BCMA were FDA DMF filed which can support your IND, NDA and BLA process.
Full length multi-pass TPs with stabilized structure and high bioactivity for immunization, antibody screening, cell based assay and CAR detection, including hot CD20, Claudin 18.2， CD133, GPRC5D，CCR8, CCR5, etc.
This web search service is supported by Google Inc.